A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma
What is the purpose of this trial?
The purpose of this trial is to assess the efficacy and safety of E7777 (improved purity ONTAK) in patients with persistent and recurrent cutaneous T-cell lymphoma. A lead-in dose-finding part will be used to determine the dose of E7777 that should be used to test efficacy and safety.
- Ages18 years and older
- Trial withEisai Pharmaceuticals
- Start Date07/18/2017
- End Date06/29/2019
- Last Updated08/27/2020
- Study HIC#2000020362